MCL1 and neoplasm: Preclinical studies demonstrating the therapeutic effect of targeting MCL-1 in haematopoietic tumours have supported the clinical application of MCL-1-specific BH3-mimetics: genetic deletion of Mcl1 potently restricts tumour expansion and enhances survival in mouse models of AML, B-cell lymphoma and T-cell lymphoma [40–42].